Science · 2020 · 421 citations · 35 references
Life SciencesImmunologyMolecular BiologyImmunotherapyMolecular ImmunologySignal TransductionAntigen RecognitionCell-mediated ImmunityT Cell ActivationT Cell Activation ControlT Cell BiologyT Cell Receptor SignalingAntigen Recognition DomainsCell ActivationT Cell Receptor StructureT Cell-based ImmunotherapyT Cell-dependent Activation
A weird way to recognize phosphoantigens In contrast to the well-studied αβ T cells, which recognize peptide antigens presented by major histocompatibility complex (MHC) and MHC-like molecules, how γδ T cells recognize antigens remains largely a mystery. One major class of γδ T cells, designated Vγ9Vδ2 + , is activated by small, phosphorylated nonpeptide antigens, or phosphoantigens, produced by microbes and cancer cells. Rigau et al. found that these cells needed the combination of two immunoglobulin superfamily members, butyrophilin 2A1 (BTN2A1) and BTN3A1, on their cell surface to recognize these phosphoantigens. BTN2A1 directly binds the Vγ9 + domain of the T cell receptor (TCR), whereas a second ligand, potentially BTN3A1, binds the Vδ2 and γ-chain regions on the opposite side of the TCR. A better understanding of this unexpected form of T cell antigen recognition should inform and enhance future γδ T cell–mediated immunotherapies. Science , this issue p. eaay5516
35
Cutadapt removes adapter sequences from high-throughput sequencing reads
Marcel Martin · EMBnet journal · 2011 · 35.8K citations · Full text
Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening
Julia Joung, Silvana Konermann, Jonathan S. Gootenberg et al. · Nature Protocols · 2017 · 1.3K citations · Full text
Natural and synthetic non-peptide antigens recognized by human γδ T cells
Yoshimasa Tanaka, Craig T. Morita, Yôko Tanaka et al. · Nature · 1995 · 1K citations
Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis
Sidi Chen, Neville E. Sanjana, Kaijie Zheng et al. · Cell · 2015 · 934 citations · Full text
Life Sciences, Genetics, Oncology +16